Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB.

Chung, C; Shin, J E; Jeon, D; Kang, H; Yim, J-J; Jo, K-W; Shim, T S

Chung, C; Shin, J E; Jeon, D; Kang, H; Yim, J-J; Jo, K-W; Shim, T S.

Affiliation

Chung C; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Shin JE; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jeon D; Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
Kang H; Department of Chest Medicine, Masan National Tuberculosis Hospital, Masan, Republic of Korea.
Yim JJ; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Jo KW; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Shim TS; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Int J Tuberc Lung Dis ; 27(2): 151-153, 2023 02 01.

Article de En | MEDLINE | ID: mdl-36853109

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tuberculose multirésistante Limites: Humans Langue: En Journal: Int J Tuberc Lung Dis Année: 2023 Type de document: Article Pays de publication: France

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google